Pharma Mar, S.A. (FRA:PMRA)

Market Cap	1.28B -19.7%
Revenue (ttm)	218.64M +15.5%
Net Income	56.13M +33.6%
EPS	3.11 +29.1%
Shares Out	n/a
PE Ratio	22.75
Forward PE	14.74
Dividend	1.00 (1.34%)
Ex-Dividend Date	Jul 8, 2026

Volume	n/a
Open	74.65
Previous Close	76.55
Day's Range	74.65 - 74.65
52-Week Range	65.50 - 105.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1986
• Employees: 505
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PMRA

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 18, 2026

Data Sources Report a data error